Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Pieczonka

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
The Lancet. Oncology|June 1, 2026
Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trialTheodore L DeWeese, Andrea Manzanera, John Sylvester, et al.
The Journal of Urology|September 3, 2024
Reply by AuthorsNeal Shore, Christopher Pieczonka, Sean Heron, et al.
The Journal of Urology|August 9, 2024
Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate CancerNeal Shore, Christopher Pieczonka, Sean Heron, et al.
Contemporary Clinical Trials|June 16, 2022
Technology-enhanced AcceleRation of Germline Evaluation for Therapy (TARGET): A randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testingStacy Loeb, Heather H Cheng, Amy Leader, et al.
European Urology Oncology|August 13, 2023
Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM TrialNeal Shore, Mukaram Gazi, Christopher Pieczonka, et al.
The Oncologist|February 23, 2024
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMISNeal D Shore, Christian Gratzke, Susan Feyerabend, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
The Lancet. Oncology|June 1, 2026
Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trialTheodore L DeWeese, Andrea Manzanera, John Sylvester, et al.
The Journal of Urology|September 3, 2024
Reply by AuthorsNeal Shore, Christopher Pieczonka, Sean Heron, et al.
The Journal of Urology|August 9, 2024
Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate CancerNeal Shore, Christopher Pieczonka, Sean Heron, et al.
Contemporary Clinical Trials|June 16, 2022
Technology-enhanced AcceleRation of Germline Evaluation for Therapy (TARGET): A randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testingStacy Loeb, Heather H Cheng, Amy Leader, et al.
European Urology Oncology|August 13, 2023
Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM TrialNeal Shore, Mukaram Gazi, Christopher Pieczonka, et al.
The Oncologist|February 23, 2024
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMISNeal D Shore, Christian Gratzke, Susan Feyerabend, et al.
Pageof 2